development dialogue paper
no.26 | december 2018
Antimicrobial resistance and sustainable development:
A planetary threat
but a financing orphan
Planet Earth faces the very real threat of having to survive and thrive in a
‘post-antibiotic’ era in which there are few, if any, antibiotics which effectively
and affordably cure infections. A world without antibiotics would necessitate
radical changes in health care and farming. Despite the severity of this threat,
many low- and middle-income countries struggle to identify resources
for even basic activities related to antimicrobial resistance (AMR).
In this context, the Dag Hammarskjöld Foundation and ReAct - Action on
Antibiotic Resistance hosted a meeting to discuss how AMR could become
more visible and how more funds to tackle AMR could be mobilised.
Photos: Adobe Stock Images
Printed by XO-Graf, Uppsala 2018
Introduction In this context, the Dag Hammarskjöld Foundation
In December 2018, a meeting was convened by the and ReAct - Action on Antibiotic Resistance – hosted
Dag Hammarskjöld Foundation and ReAct - Action on a meeting to discuss how AMR could become more
Antibiotic Resistance - to discuss funding for the global visible and how more funds to tackle AMR could be
crisis of antimicrobial resistance (AMR). Participants mobilised.
came from a variety of organisations including national
governments, multilateral and bilateral institutions, civil Antimicrobials are widely used in human and veterinary
society organisations and academia. The meeting heard medicine and agriculture, and are then dispersed into
evidence from a number of low- and middle-income the environment. The deliberations described in this
countries about the extreme difficulty in identifying document are the result of the interaction of a group of
funds for priority activities and finding people to act as global health actors. This means that not all aspects of
AMR coordinators/focal points. AMR are fully considered: it is also important to devel-
op an analysis of needs and funding options for agricul-
The meeting discussed the importance of delineating ture and the environment.
clear roles at global and country levels. In addition to
global public goods functions, a role was identified for Neither did the meeting discuss the vital issue of research
global catalytic funding to kick-start activities. AMR and development of new antimicrobials, diagnostics and
funding should also be integrated into existing pro- vaccines. This is an important, but different, strand of the
grammes that work in relevant areas. overall story about mobilising resources to tackle AMR.
Six principles for AMR funding were identified – pay
now or have to pay much more later; the form of fund- A meeting to discuss AMR financing
ing mechanisms to follow the allocation of functions; A small meeting of around 20 people took place in
harnessing existing funds to become more AMR- December 2018 to discuss how AMR activities might
oriented; global financing channels to be visible and be financed. Participants – who attended in their
accessible to countries; a health systems (not single- individual capacity – came from a variety of organisa-
programme) approach; and the promotion of sustainability. tions including national governments, multilateral and
This meeting identified five next steps for developing bilateral institutions, civil society organisations (CSOs)
concrete proposals about how to fund AMR activities: and academia.
• Explore what a global mechanism providing
catalytic funding could look like. The meeting started with country presentations from
• Develop stronger investment cases, nationally and Africa and Asia. A clear message emerged that there are
internationally. practical difficulties finding people and money to imple-
• Support country pilots to learn more about the ment AMR activities. A focal AMR-person in govern-
practical challenges of implementing an AMR ment can achieve a lot if they are allocated the time to
National Action Plan (NAP). devote to AMR and have sufficient authority to meet
• Work with relevant international funders to and influence key actors.
explore how they can adapt their work to be more
AMR-oriented. A presentation based on the report Monitoring Global
• Make it easier for countries to access catalytic Progress on Addressing AMR¹ reinforced the situation
funds, particularly for developing AMR champions, described by countries: there is a rapid tail-off from
strengthening narratives, collecting and using more the number of countries that have produced an AMR
data, and supporting countries to build their own National Action Plan to the number that are making
investment cases. significant progress with implementation.
Antimicrobial resistance: The meeting then discussed narratives about AMR and
a planetary threat but a financing orphan how AMR can be presented as part of the wider move-
Planet Earth faces the very real threat of having to sur- ment for sustainable development, given its relevance to
vive and thrive in a ‘post-antibiotic’ era in which there development concerns including poverty, equality and
are few, if any, antibiotics which effectively and afford- nutrition.
ably cure infections. A world without antibiotics would
necessitate radical changes in health care and farming. The next session explored practical examples to inform
Despite the severity of this threat, many low- and thinking about AMR financing. Relevant examples in-
middle-income countries (LMICs) struggle to identify cluded the Green Climate Fund (which works through
resources for even basic activities related to antimicrobial a number of different channels including readiness sup-
resistance. port, accreditation and funds for both project prepara-
development dialogue paper no. 26 | december 2018 3
tion and implementation), the Montreal Protocol be a clear go-to place for financial support. Some
about ozone depletion, the Global Environment Facility respondents working for donors, on the other hand,
and the Global Financing Facility related to the health were reluctant to create a new fund, partly because of
of women, children and adolescents. The meeting also the political will and work required, but also because of
discussed the relationship between AMR and exist- concerns about further fragmentation of global health
ing funding streams, with a particular focus on the funding. The meeting also highlighted that opportunities
Global Fund for AIDS, Tuberculosis (TB) and Malaria. with private sector investment such as life and health
The meeting particularly benefited from some (as yet insurance services and hospital investment programmes
unpublished) academic work based on a number of key should be further explored.
informant interviews. The preliminary results showed
how people’s opinions about the best way to fund AMR Break-out groups were set the challenge of identifying
were greatly influenced by where they were based. Most tangible financing options. A clear resulting message
respondents based in LMICs favoured some sort of was that it is important to think of different solutions at
AMR-dedicated global funding stream because it would different levels – what needs to happen in countries and
what is the role of the global level?
Frequently encountered barriers to implementing AMR activities in LMICs
• It is vital to have individuals with a designated role in moving AMR forward:
AMR focal points. They cannot be effective if they are over-burdened with other
non-AMR tasks or if the focal point role carries no authority.
• There is no go-to place for funds for the early stage of NAP implementation:
easily accessible funds for initiating activities and for pilots would be very helpful.
• For countries, an effective AMR governance structure and a costed NAP are necessary
but not sufficient: there needs to be a source of catalytic funding.
We need a convincing story to attract funds • Antibiotics have become a substitute for good
In the context of policymaking and financing, a ‘narra- quality health care. We must raise standards in
tive’ is a concise way of describing an issue and why it is basic infection prevention.
important. The meeting discussed AMR narratives: how • It is impossible to deliver Universal Health
AMR can be presented as part of the wider movement Coverage (UHC) without ensuring access to
for sustainable development and AMR’s relevance to affordable, quality antibiotics. AMR will make
development concerns including ending poverty and provision of basic essential health services more
hunger, good health, clean water, the environment and expensive and therefore delay UHC.
responsible production and consumption. • Health insurance companies frequently fund
activities related to better exercise and diet because
Developing AMR narratives is difficult but vital. AMR these investments save money over time. The
can be managed, but not completely solved; we must ac- same should apply to AMR: insurance companies
knowledge that insufficient access to antibiotics in many should demand high standards of drug stewardship
countries occurs at the same time as some populations and infection prevention and control.
use antibiotics to excess. We need to communicate the • The expansion of AMR is a huge risk because
importance of urgently tackling AMR and that if we do it threatens recent gains in key areas of global health,
not do this there will be catastrophic impacts on people’s including maternal and neonatal health, TB and
health and diets, with food and medicines becoming HIV.
more expensive and effective antimicrobials becoming • The Global Health Security Agenda was
scarcer. launched in 2014 and has quickly attracted consid-
erable attention and funding. Its aim is to create a
Examples of AMR narratives connected to major global world safe from infectious disease threats, including
health issues include: by elevating global health security to be a priority
of national leaders. AMR is an important part of
this agenda.
4 development dialogue paper no. 26 | december 2018
We need to make sure that AMR narratives are widely Each phase is different in every country and requires
heard, as this will increase the prospects of mobilising different kinds of support – technical and financial –
funding. To do this we need to identify and educate from the global and regional levels. CSOs can play a
AMR champions. pivotal role in many situations, including mobilising a
range of stakeholders and monitoring for accountability.
Narratives need to be backed up by credible data. There The nature of AMR means it is important to look at
is a great deal to be done about this in the field of AMR governance and implementation of the NAP
AMR. Existing data needs to be used to make as holistically. Tackling AMR requires change within the
effective a case as possible now; the narrative can be health system in terms of how it manages drugs and
strengthened over time as data improves. Narratives deals with infection: piecemeal funding of specific
need to be based on information about: actions can help, but are not a substitute for embedded,
• the prevalence and types of AMR (where is it a system-wide change.
problem and relating to which particular drugs?),
• illness and deaths which can be attributed to AMR, For countries without a completed NAP, the challenge
• the cost of tackling AMR and what can be achieved. is one of advocacy and practical technical support. What
steps are needed to start the development of a NAP
An investment case is a particular kind of narrative with appropriate local ownership and involvement?
which describes alternative courses of action and their Countries vary in terms of how pro-active CSOs and
implications. Investment cases about AMR – at the development partners need to be.
hospital, national, regional and global levels – need to be
developed and strengthened. Many countries are stuck at the first steps of imple-
menting NAPs (Phase 2). It is challenging to develop an
Investment cases should specify what can be done about AMR Committee that functions effectively in relation
AMR, how much that would cost and what the im- to multiple sectors and which operates through clear
pact would be. This would then be compared with the action points with accountability for implementation.
negative impacts (the costs) of doing nothing about Full-time staff in an AMR Secretariat – or at least desig-
AMR. This work would build on the World Bank’s 2017 nated sectoral focal points – are vital at this stage.
simulations, which found that by 2050 annual global
gross domestic product (GDP) could fall by as much as When countries actually start implementing priority
3.8%, relative to a base-case scenario where no AMR activities described in the NAP (Phase 3), much of the
effects were incorporated into the model. The GDP focus needs to be on working with existing players to
shortfall would exceed US$ 3.4 trillion annually after make their activities more AMR-oriented. This phase
2030. Losses would disproportionately affect low-in- may require some catalytic funding, but over time more
come countries. Investment in AMR was judged to have and more funding will come from in-country sources.
exceptionally high economic and health yields, with a
potential 88% return if 75% of AMR’s negative effects The meeting did not discuss Phase 4 in any detail. At
were avoided.² this stage, the vast majority of funding is country-based,
with a relatively small role for ongoing global functions
Phases of implementation such as data analysis and information sharing.
By 2018, 112 countries had a National Action Plan for
AMR, with a further 67 countries in the process of
developing a NAP. However only about 12% of Money for what activities, delivered
countries with NAPs had engaged all the relevant and funded by whom?
sectors and identified funding.³ It can be helpful to Whilst exploring relevant examples and discussing
think about how countries move from developing a during break-out sessions, meeting participants realised
NAP, through early start-up activities, then scaling up that it was important to be clear on what AMR
implementation and moving towards sustainability. activities were being talked about and the respective
roles of countries and the global level. Detailed
There are four identifiable phases: discussions resulted in the allocation of roles described
• Situation analysis and an approved NAP (Phase 1) in Boxes 1 and 2.
• Readiness to implement the NAP – ie establishing
the structures and people that can mobilise ‘Form follows function’ is the notion that it is import-
resources, prioritise activities and stimulate ant to be clear about who does what. In this context,
implementation (Phase 2) it means that the design of a funding stream depends
• Implementation of key priorities (Phase 3) on what activities are to be supported and who is best
• Broader implementation with sustainable financing placed to deliver these activities.
(Phase 4)
development dialogue paper no. 26 | december 2018 5
Box 1: AMR activities - global functions
Global public good
• Data collection, analysis, interpretation and sharing. (Surveillance of resistance,
the disease burden caused by AMR, antimicrobial use).
• Analysis of country progress with AMR to enable countries to compare
themselves with others. Collect and share best practices and success stories.
• Guidelines and minimum standards, with accompanying technical support.
• Coordination
- Efficient, streamlined implementation of the above functions
(key roles for the World Health Organization (WHO), Food and Agriculture
Organization (FAO), World Organisation for Animal Health (OIE),
UN Environment Programme (UN Environment)).
- Working with development partners which support relevant activities in countries:
integration of AMR into existing funding portfolios at global level.
Development partners to deliver strong, consistent messages about the importance of AMR
activities and how they can be integrated into existing work.
Catalytic function
• Catalytic funding, advocacy and technical support for countries to move through the AMR
Phases described above:
- developing a NAP,
- creating governance structures that enable NAP implementation,
- understanding how to integrate AMR into existing programmes/initiatives
and starting key workstreams within the NAP,
- moving towards sustainability.
Some areas of work, notably collecting and using data, now time to bring these ideas together in the context of
are both global and country functions. It is a national AMR financing.
function to collect data according to the country’s own
needs and also to contribute information to meet global For countries that are yet to develop a NAP or are in
requirements. It is a global responsibility to collect and the early steps of implementation (Phases 1-3), the
use this data, and to support countries which are strug- global functions related to data, coordination, guidelines
gling to collect it. and overviews of progress are all relevant. But there is
also another global function: to be catalytic. ‘Catalytic’ in
Different country phases require this sense means enabling a process to start and moving
different kinds of global support it towards being implemented with a country’s own
Having described global functions and identified resources. For Phase 1 countries, much of the catalytic
phases of NAP development and implementation, it is role is advocacy and technical support about how to
6 development dialogue paper no. 26 | december 2018
Box 2: AMR activities - country functions
The list below illustrates the range of work which needs to happen in countries. However,
the list of ‘AMR activities’ is so long and wide-reaching that it can be more useful to think
of AMR activities as a crucial element of the health system as a whole. From this
angle, the challenge is to integrate AMR-action into the overall planning and governance of
the health sector, into every health facility and programme.
• Foster political will and decisiveness, generating and using data to strengthen the case for
action on AMR.
• Develop a NAP that is formally approved.
• Establish a governance structure that can enable and monitor implementation and hold
actors accountable.
• Map who is already doing what and with what resources: government, technical institu-
tions, insurers, health providers, manufacturers, development partners, CSOs.
• Work with actors in relevant areas to encourage them to work in an AMR-oriented
way: this capitalises on existing in-country activities. Relevant areas include:
– AMR specific: antimicrobial stewardship (standard treatment guidelines, use,
quality, retail conditions); Infection Prevention and Control.
– AMR sensitive: integrate AMR into existing national programmes/institutions
including primary care, hospitals, laboratories, HIV, TB, malaria, maternal and child
health, water and sanitation (WASH), immunisation, global health security,
health worker education and essential medicines programmes.
• Allocate responsibility for AMR-specific activities which may not have an obvious
‘home’, such as awareness and behavioural change interventions.
• Human resources: understand the skills and numbers of people required and plan how to
make these available.
address AMR. In Phase 2, a key global role is to support countries is mostly about data, technical standards and
the development of effective AMR governance sharing information.
structures, as well as some financing to kick-start imple-
mentation. Phase 3 countries will also require catalytic
financing to expand the proportion of activities from the
NAP which are functioning well.
A country that is implementing and sustainably funding
its NAP (Phase 4) has largely integrated its AMR work
into national processes: the AMR response has been
institutionalised and many activities will be embedded
in ongoing national programmes. The global role in such
development dialogue paper no. 26 | december 2018 7
Figure 1: AMR financing functions during different phases of the National Action Plan
Global funding for core global functions
Phase 1 Phase 2 Phase 3 Phase 4
Phases of AMR work
Catalytic global funding In-country funding - sustained
Figure 1 depicts how the composition of AMR funding • Coordination and information-sharing.
is likely to change over time as a country develops its • Initiate country pilots:This could be in specific
NAP and proceeds with implementation. The pink line technical areas, but would ideally support the wider
shows the role of global catalytic funds: the amount of governance function of working with multiple
money required for this is likely to be highest in Phase 3 actors to make sure AMR work is happening in
when a country moves from concerns about governance their specific area of work. Share information about
and writing the NAP towards starting to implement experiences.
activities. The arrow in teal shows that there is also a • Engage with regional institutions and
fairly stable global public good element which requires programmes: All levels – global, regional and
ongoing financial support. The purple line shows national – have a role to play in ensuring that AMR
in-country funding, mostly from government and the activities are integrated wherever relevant and in as
private sector: this funding grows over time until it can consistent and cohesive a way as possible.
eventually plateau. • Work in areas where there are economies
of scale, skills shortages or other compel-
The role of regions ling technical reasons to work on behalf of a
A focus on national and global functions does not cap- number of countries. Examples could include
ture the whole picture – there is also the regional level, specialist procurement, quality control of laborato-
involving regional bodies such as the African Union and ries or analysis of drug efficacy.
the Association of Southeast Asian Nations (ASEAN).
There is great variation amongst regions in terms of ‘Regions’ refers to countries grouped geographically.
their capacity, institutional set-up and the number and The same list of functions could also apply to a group
sizes of constituent countries. of countries from different regions that are at a similar
place in the journey from Phase 1 to Phase 4.
Nevertheless, it is possible to identify some potential
functions for regions:
• Leadership: Be aware of when countries are stuck
on Phase 1 or Phase 2. Identify areas of common
concern amongst countries which would benefit
from a collective solution.
8 development dialogue paper no. 26 | december 2018
Box 3: Funding sources in addition to governments and donors
There is a risk that financing discussions focus disproportionately on funding from
governments and from donors (globally, donors contribute less than 1% of total health
expenditure).⁴ In many countries out-of-pocket spending and private sector investment such
as insurance are also very important.
One of the country functions specified in Box 2 is to have a dialogue ‘with actors in relevant
areas to encourage them to work in an AMR-oriented way’. The nature of the dialogue
– and its participants – varies according to the funding source.
Out-of-pocket expenditure. Out-of-pocket expenditure on antimicrobials typically
happens when there are gaps in public sector services and essential medicine supplies and
when consumers buy drugs from unregulated sellers. This is an extremely difficult issue to
tackle, requiring a blend of education, regulation and enforcement. Nevertheless, well-
designed and widely-disseminated messages to consumers about the quality of antibiotics
and appropriate usage, for example, could help to shift this existing spending away from
unwittingly harmful purchases of antimicrobials. If this issue is not addressed, a significant
part of overall health sector activity does not become more AMR-oriented. Universal Health
Coverage is important here, as one of its elements is to reduce reliance on out-of-pocket
spending.
Insurance. Spend-to-save arguments can make sense to insurers. AMR cases cost more to
treat than non-resistant cases; preventing infections and resistance can make financial sense.
Principles for AMR financing Given its complexity and the multiple stakeholders
So far this document has discussed the importance of involved, coordination of AMR funding is vital: part
explaining why AMR is important; the shortage of of efficient financing is to devise effective coordination
money to tackle AMR; the fact that a lot of funds are mechanisms at various levels. The need for coordination
already spent on AMR-sensitive activities; and the need is made all the more apparent when the reader is re-
to be clear about which AMR activities are best dealt minded that this paper focuses on the health sector, and
with at the national, regional and global levels. Taking that equivalent attention needs to be paid to financing
all these considerations together, it should be clear that for animal health and the environment. It makes sense
‘funding AMR’ must happen in a variety of ways for to think in terms of starting with funding mechanisms
different activities and at different levels: the challenge for animal health and the environment that are sepa-
is to describe a bundle of financing mechanisms that rate from health funding channels because this is how
combine to address AMR. The word ‘bundle’ is used governments work and because different technical skills
deliberately – this is not about a neat set of activities are required.
that fit together like a jigsaw. We need to think in terms
of tackling AMR on multiple fronts through multiple
channels.
The meeting did not go into great detail about specific
funding mechanisms, but it did identify a number of
principles for AMR funding (see Box 4).
development dialogue paper no. 26 | december 2018 9
Box 4: Principles for AMR funding
• The choice is to pay now or to have to pay much more later: this case needs to
be made persuasively to a variety of audiences.
• The form of funding mechanisms should follow the allocation of functions.
Boxes 1 and 2 described global and country roles: funding should promote this
division of labour.
• Much can be done to harness existing funds to become more AMR-oriented.
We cannot just assume that international and national players will do this: there is a
need for accountability mechanisms for being AMR-responsible.
• Global financing channels should be clearly visible and accessible for countries.
• Mechanisms should promote a health systems approach, rather than fragmentation.
• The design of financing mechanisms should promote long-term sustainability.
Some mechanisms can be explicitly short-term and catalytic.
Next steps • Is it possible for a large fund and its associated
This meeting was an early step in developing concrete bureaucracy to maintain an effective focus on being
proposals about how to fund AMR activities. A lot of catalytic?
time was spent on thinking through the implications
of the global/regional/country division of labour and 2. Develop stronger investment cases, nationally
mapping out how patterns of funding might change and internationally.
over time. There was considerable interest in mecha- • Develop tools to help countries build their own
nisms such as the Green Climate Fund and a desire to investment cases about AMR.
understand more about relevant examples. The discus- • Ensure that appropriate technical capacity exists and
sions were inevitably inconclusive, but five clear areas for make it available to support countries with this.⁶
further work emerged. • Use existing data and improve data availability,
develop convincing evidence-based narratives.
1. Explore what a global mechanism providing • Stress the implications of doing nothing or doing
catalytic funding could look like. Dialogues with too little – this is impact in terms of human health,
governments, multilateral and bilateral agencies, founda- food supplies, poverty and inequality.
tions and others can build up a picture of what is desir- • Emphasise the real risk that past improvements in
able and realistic. There are many questions to explore, health, wealth and nutrition could be reversed if the
including: world had to cope without effective antibiotics.
• Should there be an AMR-specific, stand-alone
funding channel? Or could a mechanism be housed 3. Support a small number of country pilots
within an existing institution? Which one? One or to learn more about the practical challenges in
more UN agencies? The Global Fund? Or is there implementing a NAP. This is about improving our
a need for a new set-up, for example a multi-partner understanding of what happens during Phase 3, when
trust fund? activities are beginning but are not yet institutionalised
• How much new global donor money is required and sustainable.
and how much is about re-allocating existing
funding? A crucial aspect of this is enabling one or more AMR
• Is there an appetite for developing a new funding coordinators at the country level to have time to work
source, such as a tax or levy? A relevant example to on the many strands of AMR work, with appropriate
explore is UNITAID, whose single main source of technical support and encouragement where necessary.
income is an airline ticket levy in approximately What are the real-life experiences in harnessing exist-
ten countries.⁵ ing activities to become more AMR-oriented? What
• Could results-based financing be incorporated? strategies work? What conversations need to be had and
• Could one mechanism be designed to provide funds what partnerships tend to be successful? What external
to a variety of types of organisations, including support in terms of technical assistance and finances is
governments and CSOs? required? Where do resources come from in practice?
10 development dialogue paper no. 26 | december 2018
4. Work with relevant international funders to
explore how they can adapt their work to be
more AMR-oriented. The Global Fund is one
obvious funder, as is the Global Alliance for Vaccines and
Immunization (Gavi), though this may be more in the
area of product development and procurement.
Key issues to explore with the Global Fund are the
extent to which AMR-specific activities might success-
fully be included in proposals and how to encourage
this, as well as ways to maximise work on infection
prevention and control and antimicrobial stewardship.
Would the mandate of the Global Fund need to be
extended to do this in a significant way, or is the current
mandate (including support for health systems strength-
ening) adequate?
5. Make it easier for countries to access catalytic
funds in the short term and promote specific
priorities for catalytic funding. Countries face a
very practical challenge in knowing where to go to
access funds to start the process of implementing a NAP.
There are a number of things that could be done to
improve this, ranging from basic steps such as compiling
information about possible funding sources for AMR,
to developing the global mechanism described above as
quickly as possible, perhaps with an interim arrangement
in place to speed up access to funds.
In terms of priorities for this funding, four areas were
identified. These are all catalytic activities, in that they
are about stimulating or enabling further substantive
work on AMR:
• Continue to identify and work with a wide
variety of champions to help spread understanding
about AMR.
• Develop and improve narratives and related
devices such as an ‘AMR clock’.
• Collect and use more data, including sentinel
point prevalence studies and estimates of
AMR-attributable mortality. This is to comple-
ment existing data collection funded by, amongst
others, national governments and the Fleming Fund.
• Develop a tool to help countries build their own
investment cases. Ensure that appropriate
technical capacity exists and make it available to
countries.
development dialogue paper no. 26 | december 2018 11
Endnotes
¹WHO/FAO/OIE, ‘Monitoring Global Progress on Addressing AMR’, ⁴IHME, ‘Financing Global Health’, (report, IHME, 2017). http://
(report, WHO/FAO/OIE, 2018). www.healthdata.org/sites/default/files/files/policy_report/2018/
https://www.who.int/antimicrobial-resistance/publications/Analysis- IHME_FGH_2017_fullreport.pdf
report-of-AMR-country-se/en/
⁵World Bank and GAVI Alliance, ‘Immunization Financing Toolkit:
²World Bank, ‘Drug-Resistant Infections: A Threat to Our Economic Brief 18 Innovative Financing – Airline Ticket Tax’, (toolkit, World
Future’, (report, World Bank, 2017). Bank and GAVI Alliance, 2010). https://www.who.int/immunization/
http://documents.worldbank.org/curated/en/323311493396993758/ programmes_systems/financing/tools/final_toolkit_2011.pdf ?ua=1
pdf/114679-REVISED-v2-Drug-Resistant-Infections-Final-Report.pdf
⁶The collaborative Project on Medicine Prices and Availability by
³WHO/FAO/OIE ‘Monitoring Global Progress on Addressing AMR’, WHO and the NGO Health Action International is a potentially useful
(report, WHO/FAO/OIE, 2018). model for how this could work.
This paper was prepared by the Dag Hammarskjöld Foundation and ReAct. It was edited by
Catriona Waddington, based on contributions from the meeting participants. It builds on background
documents provided to the participants and processes and synthesises discussions. All contributors spoke
in their personal capacities and not on behalf of the organisations or governments to which they belong.
Participants were:
Karin Abbor-Svensson, Dag Hammarskjöld Foundation
Håkan Björkman, UNDP
Otto Cars, ReAct
Sujith Chandy, ReAct
Yoke Ling Chee (by video-conference), Third World Network
Carlos Correa, South Centre
Kim Faure, Mediclinic South Africa
Tracie Muraya, ReAct
Anders Nordström, Swedish Ministry of Foreign Affairs
Ejike Nwokoro, University of Bergen
Trygve Ottersen, Norwegian Institute of Public Health
Charles “Ok” Pannenborg, former Chief Adviser and Director, World Bank
Stefan Swartling Peterson, UNICEF
Mengying Ren, ReAct
Andreas Sandgren, ReAct
Anthony So, ReAct
Liz Tayler, WHO
Göran Tomson, Karolinska Institutet
Maarten van der Heijden, ReAct
Catriona Waddington, Mott MacDonald
This paper was prepared by the Dag Hammarskjöld Foundation and ReAct
ReAct - Action on Antibiotic Resistance
is an independent global network for
concerted action on antibiotic resistance
www.reactgroup.org
The Development Dialogue paper series
is published by the Dag Hammarskjöld
Foundation and aims to provide analysis
and practical recommendations on
important development issues. www.daghammarskjold.se
[email protected]
Saatja: Anna Zorzet <
[email protected]>
Saadetud: 28.02.2019 14:34
Adressaat: Anna Zorzet <
[email protected]>
Koopia: Andreas Sandgren <
[email protected]>; Otto Cars
<
[email protected]>
Teema: New report on Antibiotic Resistance and Sustainable Development
Dear Minister of Health,It is our great pleasure to share with you a new
report: When the Drugs Dont Work - Antibiotic Resistance as a Global
Development Problem, by ReAct and the Dag Hammarskjöld Foundation. The
(also attached) provides concrete examples of the impacts of antibiotic
resistance across different Sustainable Development Goals. Antibiotic
resistance would seriously jeopardise the achievement of several of the
Sustainable Development Goals related to poverty, health, food production
and hunger, economic growth, inequality and the environment.The report is
intended to inform and stimulate discussions on how to further advance
the implementation of:- 2030 Agenda for Sustainable Development,-
Global Action Plan on Antimicrobial Resistance,- National Action
plans on Antimicrobial Resistance, and- Work within all sectors
that affect and are affected by antibiotic resistance.These discussions
must lead to decisions and concrete action on this urgent challenge, for
which solutions must build on a systems perspective across sectors.
Antibiotic resistance is a consequence of systems failures and should
therefore be seen and addressed through a systems perspective. To limit
the effects of antibiotic resistance, it must be considered a critical
sustainable development issue. To achieve progress to meet this
challenge, political will and action is urgently needed.It is equally
critical to meet the funding needs for tackling antibiotic resistance
with adequate resources and capacities. Last December, ReAct and the Dag
Hammarskjöld Foundation jointly organized a meeting as an early step in
discussing options for concrete proposals on how to fund sustainable
action on antibiotic resistance in line with needed functions at global
and country levels. The discussion outcomes were summarized in a meeting
report that is also attached. We invite you to lead further discussions
around this critical topic on antibiotic resistance and sustainable
development. We hope that the analyses and deliberations in both reports
will stimulate further dialogues and lead to decisions and concrete
action across sectors. Your feedback and comments are most welcome and we
look forward to continuing the active engagement and moving forward
action on antibiotic resistance.Sincerely,
Anna Zorzet, MSc, PhD
Head of ReAct Europe
ReAct - Action on Antibiotic Resistance
Uppsala University, Box 256, 751 05 Uppsala, Sweden
Phone: +46 (0)18 471 66 76
E-mail: Website: www.reactgroup.org
Facebook: Twitter: @reactgroup
När du har kontakt med oss på Uppsala universitet med e-post så innebär
det att vi behandlar dina personuppgifter. För att läsa mer om hur vi gör
det kan du läsa här: http://www.uu.se/om-uu/dataskydd-personuppgifter/ E-
mailing Uppsala University means that we will process your personal data.
For more information on how this is performed, please read here:
http://www.uu.se/en/about-uu/data-protection-policy